JPH0959184A - Enteric packaging method - Google Patents

Enteric packaging method

Info

Publication number
JPH0959184A
JPH0959184A JP23893395A JP23893395A JPH0959184A JP H0959184 A JPH0959184 A JP H0959184A JP 23893395 A JP23893395 A JP 23893395A JP 23893395 A JP23893395 A JP 23893395A JP H0959184 A JPH0959184 A JP H0959184A
Authority
JP
Japan
Prior art keywords
enteric
seaweed
extract
packaging
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP23893395A
Other languages
Japanese (ja)
Inventor
Shintaro Tashiro
信太郎 田代
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP23893395A priority Critical patent/JPH0959184A/en
Priority to PCT/AU1995/000821 priority patent/WO1996017599A1/en
Priority to AU41122/96A priority patent/AU691376B2/en
Priority to EP95939187A priority patent/EP0794769A4/en
Priority to US08/849,367 priority patent/US5958450A/en
Priority to CA002206691A priority patent/CA2206691A1/en
Publication of JPH0959184A publication Critical patent/JPH0959184A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To seal various drugs, health foods, etc., for oral administration with an enteric package to protect the drug, etc., from the gastric juice in the stomach which is the 1st organ accepting the swallowed drug package and start the disintegration by contacting with intestinal juice in the intestine to easily release the content into the small intestine. SOLUTION: The enteric packaging of a drug or a health food is performed by applying a coating agent having the acid resistance characteristic to WAKAME seaweed (Undaria pinnatifida) as well as the water-resistance of barium and produced by using an extract (1) of the leaf of seaweed such as WAKAME seaweed as a main component and adding barium sulfate thereto. As an alternative, the enteric packaging of a drug or a health food is performed by using a capsule produced by utilizing a new material composed of a liquid mixture of gelate and an extract (2) having high acid resistance and water resistance.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、腸での放出が望まれる
医薬品、健康食品等を密封包装して経口嚥下するにあた
り、胃においては胃酸から隔離、保護し、次いで腸に入
り腸液に接触するや容易に包装部分が崩壊して、内容物
である医薬品、健康食品等を腸内で放出せしめることが
できる腸溶性包装方法に関する。
BACKGROUND OF THE INVENTION The present invention, in the case of hermetically packaging medicines, health foods, etc., which are desired to be released in the intestine and swallowing them orally, isolates and protects from stomach acid in the stomach, and then enters the intestine to contact with intestinal fluid. The present invention relates to an enteric packaging method capable of easily disintegrating the packaging portion and releasing the contents such as medicines and health foods in the intestine.

【0002】[0002]

【従来の技術】従来、腸溶性包装は主として顆粒剤、丸
薬、錠剤あるいはカプセル剤として、例えば、白糖、澱
粉、タルク、ゴム、ブドウ糖、結晶セルローズ、乳糖、
炭酸カルシウム、ゼラチン、カゼイン、アルギン酸塩、
ジランガムなどの一っもしくは二つ以上の材料を使用し
て一層または多層構造の被覆、保護層を形成することが
行なわれている。
2. Description of the Related Art Heretofore, enteric-coated packaging has been mainly used as granules, pills, tablets or capsules, for example, sucrose, starch, talc, gum, glucose, crystalline cellulose, lactose,
Calcium carbonate, gelatin, casein, alginate,
It has been practiced to form one-layer or multi-layer coatings and protective layers using one or more materials such as dilan gum.

【0003】[0003]

【発明が解決しようとする課題】上記[Problems to be Solved by the Invention]

【従来の技術】で示したような腸溶性包装体は、多くの
場合、嚥下後強力な胃酸で包装が損なわれ、内容物の効
果が殆ど失われたり、または包装を強固にしたあまり、
胃ではおろか腸においても包装が崩壊せず原形のまま体
外に排泄されることもあり、人により、また時により、
胃、腸内環境が変動して一定でないこともあり、適切な
腸溶性包装方法の選択、適用が必ずしも容易でないこと
が現実に関係医療当事者において認められている。
2. Description of the Related Art In many cases, the enteric-coated package as shown in 2. Description of the Related Art after swallowing, strong gastric acid impairs the packaging, and the effect of the contents is almost lost, or the packaging is too strong.
In the stomach as well as in the intestines, the packaging may not be collapsed and may be excreted in its original form outside the body.
It is actually recognized by the medical personnel concerned that it is not always easy to select and apply an appropriate enteric coating method because the environment of the stomach and intestines may fluctuate and not be constant.

【0004】[0004]

【課題を解決するための手段】本発明では、海藻葉体
(特に塩蔵わかめ)より抽出した抽出液には、天然のア
ルギン酸ナトリゥムや短繊維のほか、燐、鉄、カルシゥ
ム、カリゥム等の成分構造により、しなやかで丈夫で、
胃液(塩酸、食塩主体)耐性があって胃中では崩壊しな
いが、腸液(アルカリ性、燐酸水素カリゥム主体)耐性
はなく、腸中で腸液と接触すると容易に崩壊し始める性
質を有している。海藻葉体より抽出した粘調液は、葉体
に含有していると思われるカルシゥム成分が、海藻葉体
の主要構成成分であるアルギン酸ナトリゥムの一部ナト
リゥムと置換して水不溶性のアルギン酸カルシゥムに変
化して安定化に寄与しているものと考えられる。このよ
うな強力な層も、弱アルカリ性である腸液に接触する
と、容易に崩壊を始め、包装主体部分の海藻葉体抽出
液、短繊維の崩壊と共に、速やか内容物の腸内放出を実
現する環境にに変わる。
In the present invention, the extract extracted from the seaweed thalli (especially salted wakame seaweed) contains natural sodium alginate and short fibers as well as phosphorus, iron, calcium, potassium and other constituent structures. It is supple and durable,
It is resistant to gastric juice (mainly hydrochloric acid and salt) and does not disintegrate in the stomach, but is not resistant to intestinal juice (alkaline, mainly potassium hydrogen phosphate) and has the property of beginning to disintegrate when it comes into contact with intestinal juice in the intestine. In the viscous liquid extracted from the seaweed leaf body, the calcium component that seems to be contained in the leaf body was replaced with a part of sodium alginate sodium, which is the main constituent of the seaweed leaf body, to form water-insoluble calcium alginate. It is thought that they have changed and contributed to stabilization. Even such a strong layer easily begins to disintegrate when it comes into contact with the intestinal fluid that is weakly alkaline, and the seaweed leaf extract and short fibers in the packaging main part disintegrate, as well as an environment that promptly releases the contents into the intestine. Changes to.

【0005】[0005]

【作用】本発明では、海藻葉体より抽出した抽出液を用
いて医薬品、健康食品等を通常、室温で包装すること
で、内容物を包装工程中、高温で損なうことなしに、胃
中では胃酸に耐えて崩壊せず、次いで腸に入るや直ちに
軟化する。わかめ、こんぶ等は通常食用に供されるもの
であり、腸内で消化されることは公知の事実であり、腸
液の作用を受けて容易に崩壊し、内容物を、胃腸内環境
変動にほとんど支配されることなしに安定して腸内で放
出せしめうる腸溶性包装を実現することができる。
In the present invention, a medicine, health food, etc. are usually packaged at room temperature using an extract extracted from seaweed leaves, so that the contents are not damaged in the stomach during the packaging process at high temperature. It withstands gastric acid and does not disintegrate, then softens immediately upon entering the intestine. Wakame seaweed, kelp, etc. are usually used for food, and it is a known fact that they are digested in the intestine. They are easily disintegrated by the action of intestinal fluid, and their contents are almost free from changes in the gastrointestinal environment. It is possible to realize an enteric package that can be stably released in the intestine without being dominated.

【0006】[0006]

【実施例】【Example】

実施例1 湯通し塩蔵わかめを水洗して塩分、挟雑物を除去し、水
または微温湯に炭酸水素ナトリゥムを微量加え浸漬、放
置する。5〜10分後、わかめは、吸水、膨張して4〜
5倍の大きさに拡大する。わかめを取り出し水切りをし
て木綿布、(手ぬぐい程度のメッシ)ナイロン布の中に
入れ、包み、製餡の要領にて搾り出すと粘調性の強い1
500cps〜2000cpsの粘度の抽出液(1)を
得る。抽出液(1)に重量比6%の硫酸バリウムを混合
した液は、耐酸性と耐水性共にすぐれた抽出液(2)を
得る。またこの抽出液(1)9部に硫酸バリウムを重量
比30%、及び板状ゼラチン、または粉末ゼラチン1部
を加え湯煎、分散させ、離型性のよいポリエチ、ポリプ
ロ等の平台上にて自然乾燥すると、酸に強く、弱アルカ
リに弱い薄板を得られる。これを素材としてカプセルを
造り薬剤充填飲用すると腸溶性包装に最適な条件を具備
した新素材になる。
Example 1 A blanched salted wakame seaweed was washed with water to remove salt and impurities, and a small amount of sodium hydrogencarbonate was added to water or lukewarm water to allow it to stand. After 5 to 10 minutes, the wakame absorbs water and expands to 4 to
Expand to 5 times the size. Take out the wakame seaweed, drain it, put it in a cotton cloth, (mesh cloth about the size of a washcloth), nylon cloth, wrap it, and squeeze it out in the manner of bean jam.
An extract (1) having a viscosity of 500 cps to 2000 cps is obtained. The liquid obtained by mixing the extraction liquid (1) with 6% by weight of barium sulfate gives the extraction liquid (2) having excellent acid resistance and water resistance. Barium sulfate (30% by weight) and plate gelatin or powder gelatin (1 part) were added to 9 parts of this extract (1), and the mixture was boiled in water and dispersed, and then placed on a flat stand such as polyethylene or polypropylene which has good mold release properties. When dried, a thin plate that is strong against acid and weak against weak alkali can be obtained. Using this as a raw material to make capsules and to drink medicine, it becomes a new raw material with optimal conditions for enteric coating.

【0007】実施例2 わかめ抽出液(1)に硫酸バリウムを混合攪拌してわか
め抽出液(2)を得た。 わかめ抽出液(1) 94g 硫酸バリウム 6g 計 100g
Example 2 Seaweed extract (1) was mixed with barium sulfate and stirred to obtain seaweed extract (2). Seaweed extract (1) 94g Barium sulfate 6g Total 100g

【0008】実施例3 実施例1の抽出液(1)および実施例2の抽出液(2)
を、市販のゼラチン、カプセル(#00)の中に細粒ビ
フィズス菌(健保薬)を0、8g充填密封したカプセル
の2個に、それぞれ抽出液(1)を、他のカプセルに抽
出液(2)をどぶ漬けして、冷蔵庫にて10時間程乾燥
して出来た包装体を抽出液(1)のカプセルは検体
(1)、抽出液(2)のカプセルは検体(2)とする。
Example 3 Extract (1) of Example 1 and Extract (2) of Example 2
The commercially available gelatin and capsules (# 00) were filled with 0 to 8 g of fine-grained bifidobacteria (health-prevention medicine) and sealed in two capsules. The capsules of the extract (1) are used as the sample (1) and the capsules of the extract (2) are used as the sample (2).

【0009】実施例4 次に日本薬局方による腸溶性崩壊試験の結果を示す。
供試検体包装体数は、それぞれ6個。 第1液(人工胃液) 第2液(人工腸液) 検体(1) 6個すべて1時間で崩壊せず 6個すべて5分で崩壊 検体(2) 6個すべて2時間で崩壊せず 6個すべて5分で崩壊
Example 4 Next, the results of an enteric disintegration test according to the Japanese Pharmacopoeia are shown.
The number of test sample packages is 6, respectively. 1st liquid (artificial gastric juice) 2nd liquid (artificial intestinal fluid) Specimen (1) 6 pieces All did not disintegrate in 1 hour 6 pieces Disintegrate in 5 minutes Specimen (2) 6 pieces Not disintegrate in 2 hours All 6 pieces Collapses in 5 minutes

【0010】また、検体(1)、検体(2)の各種酸性
水溶液についての浸漬試験結果は下表の通りであった。 酸性水溶液 検体 (1) 検体 (2) 10%塩酸 1時間後も、剥離、崩壊なし 20% 酢酸 1時間後も、剥離、崩壊なし 人工胃液(日本薬局方pH1、2) 1時間後も、剥離、崩壊なし
Further, the results of the immersion test for various acidic aqueous solutions of the specimens (1) and (2) are shown in the table below. Acidic aqueous solution Specimen (1) Specimen (2) 10% hydrochloric acid 1 hour after exfoliation, no disintegration 20% Acetic acid 1 hour exfoliation, no disintegration Artificial gastric juice (Japanese Pharmacopoeia pH 1, 2) Exfoliation after 1 hour , No collapse

【0011】次ぎに人工胃液(pH1、2)に1時間浸
漬後、取り出して各種アルカリ性水溶液に浸漬した結果
は下表の通りであった。 アルカリ性水溶液 検体(1) 検体(2) 燐酸水素カリウム(pH6、8) 5分以内で剥離、白化、崩壊が始まる 人工腸液(日本薬局方pH7、5) 3分以内で剥離、白化、崩壊が始まる
Next, the results obtained by immersing in artificial gastric juice (pH 1, 2) for 1 hour, taking out and immersing in various alkaline aqueous solutions are shown in the table below. Alkaline aqueous solution Specimen (1) Specimen (2) Potassium hydrogen phosphate (pH 6, 8) Peeling, whitening, and disintegration within 5 minutes Artificial intestinal fluid (JPP pH 7, 5) Peeling, whitening, and disintegration within 3 minutes

【0012】検体(1)、検体(2)は酸性水溶液中で
の浸漬により、接着部の溶解や包装体の崩壊がないばか
りでなく、むしろより強靭になることが観察された。通
常、わかめは酢のもので固さを増すことはよく知られて
いる。抽出液(1)、抽出液(2)は本質的に親水性で
水に膨潤する性質があるが、人工胃液(pH1、2)に
検体(1)、検体(2)を1時間浸漬した後、メスで開
封し内容物を調べたところ、外皮は軟化と弾性が増進し
ていても内容物を観察したところ、内容物に変化は特に
見られず乾燥した薬剤が現れた。胃の蠕動にも充分耐え
うるものと考えられる。
It was observed that the specimens (1) and (2) were not only dissolved in the adhesive part and collapsed in the package, but also became stronger by the immersion in the acidic aqueous solution. It is well known that seaweed is usually made of vinegar to increase its hardness. The extract (1) and the extract (2) are essentially hydrophilic and have a property of swelling in water, but after immersing the specimen (1) and the specimen (2) in artificial gastric juice (pH 1, 2) for 1 hour When the contents were opened with a scalpel and examined, the contents were observed even though the outer skin was softened and the elasticity was enhanced. No particular change was observed in the contents, and a dry drug appeared. It is considered to be able to withstand the peristalsis of the stomach.

【0013】[0013]

【発明の効果】本発明は、以上に説明したように構成さ
れているので、以下に記載されるような効果を発現す
る。
Since the present invention is constructed as described above, it exhibits the effects as described below.

【0014】一般に、胃中で薬物効果、或は健康食品効
果を期待されているものは制酸剤、胃潰瘍、咽喉用等の
薬など僅かであり、大部分は腸溶性、腸吸収性、腸内活
動性などが期待されている。しかしながら、既に述べた
ように、胃酸に耐え、腸内で内容物を放出するための適
切な包装方法が、かならずしも満足して用いられている
といえないことは、医療関係方面でよく知られている。
本発明の包装方法によって、包装保護された経口的に
服用する散剤、顆粒剤、丸薬、錠剤、カプセル剤などの
医薬品や、クロレラ、ビール酵母、乳酸菌、ロイヤルゼ
リーなどの健康食品にあっては、内容物をゼラチン、カ
プセルに充填するか、ゼリー状丸薬に直接表面加工をす
かして完成する。経口服用も水を用いればただちに柔軟
化するため、楽に嚥下でき、胃に入っても滞留時間の長
短にかかわらず包装が胃酸に侵されることがなく、次ぎ
にアルカリ性の腸液に接触して、ただちに包装の崩壊が
始まり、内容物を元の状態のまま腸内に放出することが
可能になる。
In general, only a few drugs are expected to have a drug effect or a health food effect in the stomach, such as antacids, gastric ulcers, and drugs for throat. Internal activity is expected. However, as already mentioned, it is well known in the medical field that a proper packaging method for withstanding gastric acid and releasing the contents in the intestine is not always used satisfactorily. There is.
By the packaging method of the present invention, orally-administered powders, which are packaged and protected, granules, pills, tablets, pharmaceuticals such as capsules, and chlorella, brewer's yeast, lactic acid bacteria, in health foods such as Royal Jelly, It is completed by filling the contents with gelatin, capsules or by directly surface-treating the jelly-like pills. When taken orally, water softens immediately so that it can be swallowed easily, and even if it enters the stomach, the package will not be attacked by gastric acid regardless of the length of residence time.Next, it will come into contact with alkaline intestinal fluid and immediately. The packaging begins to disintegrate and the contents can be released in their intestine in their original condition.

【0015】例えば、本発明の包装方法によれば大腸内
に必須なビフィズス菌(幼児には多く、加齢と共に次第
に減少し、老齢では殆どなく、大腸菌のみ増殖される)
も何ら損なわれることなく、胃を通過して腸内に移送放
出され小腸より大腸への経過時間と適切な腹温で発酵さ
れ幼児のような腸内状態を保ち、腸蠕動運動を活発化し
ビタミン摂取も容易になり、下痢、ガスの無臭化及び常
習便秘を改善することができる。また、将来、本発明方
法の適用により、医家向薬剤の力価の適量化とそれにと
もなう薬害の減少も考えられるので、研究の余地が多
く、抗癌剤、抗精神薬、多くの抗生物質等に幅広く応用
され、利用され得るものである。
For example, according to the packaging method of the present invention, essential bifidobacteria in the large intestine (a large number of infants, decrease gradually with aging, hardly grow in old age, only E. coli grows)
Without being impaired at all, it is transported and released through the stomach into the intestine, and is fermented with the elapsed time from the small intestine to the large intestine and at an appropriate abdominal temperature to maintain the intestinal condition of an infant and activate the intestinal peristalsis and vitamins. Ingestion becomes easy, and diarrhea, deodorization of gas, and habitual constipation can be improved. Further, in the future, by applying the method of the present invention, it is possible to optimize the titer of the drug for medics and reduce the phytotoxicity accompanying it, so there is much room for research, and it is widely applied to anticancer agents, antipsychotics, many antibiotics, etc. It can be applied and used.

【0016】本発明の特徴の一つは、内容物の充填、開
口部分の接着、密封工程が、すべて室温付近で行なえる
ことであり、加熱を嫌う内容物の場合、とくに本発明の
包装方法が有用である。
One of the features of the present invention is that the filling of the contents, the adhesion of the opening, and the sealing process can all be carried out at around room temperature, and in the case of contents that do not want to be heated, the packaging method of the present invention is particularly preferable. Is useful.

【0017】市販のゼリー質包装による丸薬(内容薬剤
ロイヤルゼリー)、樹脂質包装による丸薬(内容薬剤ビ
タミン、E。C)、硬質打抜錠(ビフィズス菌)以上外
国製品をpH1、2の人工胃液にて試験した。すべて1
5分〜20分にて崩壊したが、抽出液(2)に処理され
た包装薬はすべて1時間崩壊しなかった。更に抽出液
(2)による処理は1回よりは2回、3回のほうが外皮
が強靭であることが確認された。
Commercially available pills packed in jelly (commercial drug Royal Jelly), pills packed in resin (composition drug vitamins, E.C), hard punched tablets (bifidobacteria) and foreign products of pH 1 and 2 artificial gastric juice. It was tested in. All 1
Although it disintegrated in 5 to 20 minutes, all the packaged drugs treated with the extract (2) did not disintegrate for 1 hour. Furthermore, it was confirmed that the treatment with the extract (2) was tougher twice or three times than once.

【0018】わかめ抽出液(2)には耐水性強化の為
の、わずかな硫酸バリウムが含有されているので、乾燥
した外皮がレントゲン造影剤の役目をする。症例実験と
して3個のカプセルに生ビフィズス菌を充填、抽出液
(2)にてどぶ漬け処理、乾燥したカプセルを経口服用
後撮影した。飲用直後3分、20分、30分、60分の
観察したところ、3粒とも形状の変化、崩壊はまったく
なく、60分〜70分後幽門付近にてやや変形、その後
直ちに崩壊消失しているのが、小腸入口にて確認され
た。これは日本薬局方B−356崩壊試験法注13の9
局、10局に適合している。
Since the seaweed extract (2) contains a small amount of barium sulfate for enhancing the water resistance, the dried outer skin serves as an X-ray contrast medium. As a case experiment, three capsules were filled with live bifidobacteria, dipped in extract (2), and dried capsules were taken after oral administration. When observed for 3 minutes, 20 minutes, 30 minutes, and 60 minutes immediately after drinking, there was no change in shape or disintegration of all three grains, and after 60 to 70 minutes, some deformation occurred near the pylorus, and then collapsed and disappeared immediately. Was confirmed at the entrance of the small intestine. This is 9 of the Japanese Pharmacopoeia B-356 disintegration test method Note 13
It is suitable for 10 stations.

─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───

【手続補正書】[Procedure amendment]

【提出日】平成8年1月22日[Submission date] January 22, 1996

【手続補正1】[Procedure amendment 1]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】請求項4[Correction target item name] Claim 4

【補正方法】変更[Correction method] Change

【補正内容】[Correction contents]

【手続補正2】[Procedure amendment 2]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0006[Correction target item name] 0006

【補正方法】変更[Correction method] Change

【補正内容】[Correction contents]

【0006】[0006]

【実施例】 実施例1 湯通し塩蔵わかめを水洗して塩分、挟雑物を除去し、水
または微温湯に炭酸水素ナトリゥムを微量加え浸漬、放
置する。5〜10時間後、わかめは、吸水、膨張して4
〜5倍の大きさに拡大する。わかめを取り出して水切り
をして木綿布、(手ぬぐい程度のメッシ)ナイロン布の
中に入れ、包み、製餡の要領にて搾り出すと粘調性の強
い1500cps〜2000cpsの粘度の抽出液
(1)を得る。この抽出液(1)に重量比6%の硫酸バ
リウムを混合した液は、耐酸性と耐水性共にすぐれた抽
出液(2)を得、既存のゼラチンカプセルに塗布したカ
プセルは胃中にてX線写真撮影に反応する。 またこの
抽出液(1)を6部〜9部、板状ゼラチン、または粉末
ゼラチン4部〜1部を合計10部になるよう組み合わ
せ、湯煎にて混ぜ、更に全重量比の7%の硫酸バリウム
を溶融させると抽出液(3)ができる。抽出液(3)を
離型性のよいポリエチレン、ポリプロピレン、テフロン
コート等の型台上にて冷風乾燥すると、酸に強く、アル
カリに弱い薄膜を得られカプセルをつくる事が出来る。
また抽出液(2)または(3)を既存のゼラチンカプセ
ルや打抜錠剤に塗布すると腸溶性包装に最適な条件を具
備した新包装材になる。
Example 1 A blanched salted wakame seaweed is washed with water to remove salt and impurities, and a small amount of sodium hydrogencarbonate is added to water or slightly warm water for immersion and standing. After 5 to 10 hours , the seaweed absorbs water and expands to 4
Expand to ~ 5 times the size. Take out the wakame seaweed, drain it, put it in a cotton cloth, (mesh cloth about the size of a towel), wrap it, and squeeze it out in the manner of bean jam. It has a viscous strength of 1500 cps to 2000 cps. ) Get. A liquid obtained by mixing 6% by weight of barium sulfate with this extraction liquid (1) gave an extraction liquid (2) having excellent acid resistance and water resistance, and was applied to an existing gelatin capsule.
Pucelle responds to radiography in the stomach . Further , 6 to 9 parts of this extract (1) , plate gelatin, or powder
Combine 4 to 1 parts of gelatin to make a total of 10 parts
Let it mix with hot water, and then add 7% of the total weight of barium sulfate.
When melted, an extract (3) is formed. Extract (3) the <br/> releasability good Polyethylene, Polypropylene, teflon
By drying with a cold air on a mold stand such as a coat, a thin film that is strong against acid and weak against alkali can be obtained to form capsules.
In addition, extract (2) or (3) should be added to the existing gelatin capsule.
When applied to capsules and punched tablets, it becomes a new packaging material with optimal conditions for enteric coating .

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 //(A61K 47/46 47:02) (A61K 47/46 47:02 47:42) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display location // (A61K 47/46 47:02 47:42)

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 海藻類の葉体より抽出した成分を主部分
としてつくられた抽出液を密封材料として用いることか
らなる医薬品、健康食品等用腸溶性包装方法。
1. An enteric packaging method for pharmaceuticals, health foods, etc., which comprises using as an encapsulating material an extract prepared from the components extracted from the leaves of seaweed as a main part.
【請求項2】 請求項1の海藻が、わかめ、こんぶであ
る医薬品、健康食品等用腸溶性包装方法。
2. An enteric packaging method for pharmaceuticals, health foods, etc., wherein the seaweed of claim 1 is seaweed or kelp.
【請求項3】 わかめより抽出した各種成分を含む抽出
液に、または、その抽出液に硫酸バリウムを加えた混合
液を医薬品、健康食品等用腸溶性を必要とする包装材に
塗布して使用する包装方法。
3. Use of an extract containing various components extracted from wakame seaweed, or a mixture of barium sulfate added to the extract applied to a packaging material for pharmaceuticals, health foods, etc. which requires enteric properties. Packaging method.
【請求項4】 わかめより抽出した各種成分を含む抽出
液に硫酸バリウムを加えた混合液を主体にして、ゼラチ
ンを添加し混合、湯煎、乾燥した素材でカプセル等の包
装材を作り医薬品、健康食品等用腸溶性包装に用いる包
装方法。
4. A packaging material such as a capsule made of a mixture of barium sulfate added to an extract containing various components extracted from wakame seaweed, mixed with gelatin, boiled in water and dried to make medicines and health products. A packaging method used for enteric packaging for food and the like.
JP23893395A 1994-12-05 1995-08-14 Enteric packaging method Pending JPH0959184A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP23893395A JPH0959184A (en) 1995-08-14 1995-08-14 Enteric packaging method
PCT/AU1995/000821 WO1996017599A1 (en) 1994-12-05 1995-12-05 Method of drug delivery and coatings for use in the method
AU41122/96A AU691376B2 (en) 1994-12-05 1995-12-05 Method of drug delivery and coatings for use in the method
EP95939187A EP0794769A4 (en) 1994-12-05 1995-12-05 Method of drug delivery and coatings for use in the method
US08/849,367 US5958450A (en) 1994-12-05 1995-12-05 Method of drug delivery and coated oral dosage forms for use in the method
CA002206691A CA2206691A1 (en) 1994-12-05 1995-12-05 Method of drug delivery and coatings for use in the method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23893395A JPH0959184A (en) 1995-08-14 1995-08-14 Enteric packaging method

Publications (1)

Publication Number Publication Date
JPH0959184A true JPH0959184A (en) 1997-03-04

Family

ID=17037442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP23893395A Pending JPH0959184A (en) 1994-12-05 1995-08-14 Enteric packaging method

Country Status (1)

Country Link
JP (1) JPH0959184A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103445965A (en) * 2013-08-29 2013-12-18 广东环球制药有限公司 Method for preparing tablets containing high-dose oily components

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103445965A (en) * 2013-08-29 2013-12-18 广东环球制药有限公司 Method for preparing tablets containing high-dose oily components
CN103445965B (en) * 2013-08-29 2015-03-18 广东环球制药有限公司 Method for preparing tablets containing high-dose oily components

Similar Documents

Publication Publication Date Title
CA1054056A (en) Solid therapeutic preparation remaining in stomach
KR0155563B1 (en) Large intestinal dissociative hard capsules
US5023245A (en) Improved niacin formulation
US4555399A (en) Aspirin tablet
JP4088420B2 (en) Colon selective drug delivery composition and pharmaceutical preparation using polysaccharides
FI77371B (en) FOERFARANDE FOER FRAMSTAELLNING AV EN KAPSEL, SOM INNEHAOLLER ETT ALKALISKT AEMNE OCH ACETYLSALICYLSYRA.
US4587118A (en) Dry sustained release theophylline oral formulation
CN108601744A (en) Oral Cholestyramine preparation and application thereof
EP0466566A2 (en) Coated solid medicament form having releasebility in large intestine
JP2002138035A (en) Method for sealing capsule
JP2003504326A (en) Film-forming composition containing modified starch and iota-carrageenan and method for producing soft capsule using the same
US5364636A (en) Inhibitor of absorption of digestion product of food and drink
NO137451B (en) PROCEDURES FOR THE MANUFACTURE OF LOW CARBON BAR MATERIAL} L
KR102519593B1 (en) enteric capsules
US5958450A (en) Method of drug delivery and coated oral dosage forms for use in the method
JPS61151127A (en) Production of soft capsule containing bifidus bacteria
US2369218A (en) Preparations of scarlet fever toxin for administration by mouth
JP2931811B2 (en) Sustained release capsule
JPH0959184A (en) Enteric packaging method
JPH03988B2 (en)
CN112472715B (en) Sodium bicarbonate enteric capsule and preparation method thereof
Wagner et al. Enteric coatings IV. In Vivo testing of granules and tablets coated with styrene‐maleic acid copolymer
CN108142935A (en) A kind of slimming capsule that natural polymer subbase gel inner nuclear material is controllably constructed based on dynamic chemical key
JPH10509982A (en) Introduction of NSAIDs using powdered hydrocolloid rubber obtained from higher plants
CN113521067B (en) Famotidine zinc gluconate preparation composition and preparation method thereof